NeuroPace, Inc. (NASDAQ:NPCE) Given Consensus Rating of “Moderate Buy” by Brokerages

NeuroPace, Inc. (NASDAQ:NPCE) has earned an average recommendation of “Moderate Buy” from the six brokerages that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $15.00.

A number of equities analysts have weighed in on the company. Wells Fargo & Company lowered their price objective on NeuroPace from $15.00 to $13.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 13th. JPMorgan Chase & Co. upped their price target on NeuroPace from $9.00 to $14.00 and gave the company an “overweight” rating in a research note on Tuesday, December 17th.

Insider Activity

In related news, major shareholder Ltd. Kck sold 223,991 shares of the business’s stock in a transaction on Friday, October 25th. The stock was sold at an average price of $5.45, for a total value of $1,220,750.95. Following the sale, the insider now owns 5,270,845 shares in the company, valued at approximately $28,726,105.25. The trade was a 4.08 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold a total of 227,858 shares of company stock valued at $1,244,328 in the last quarter. Insiders own 22.20% of the company’s stock.

Institutional Investors Weigh In On NeuroPace

Several institutional investors and hedge funds have recently modified their holdings of the company. KCK LTD. purchased a new stake in shares of NeuroPace in the 4th quarter valued at $58,981,000. Millennium Management LLC raised its holdings in shares of NeuroPace by 13.3% in the 2nd quarter. Millennium Management LLC now owns 686,037 shares of the company’s stock valued at $5,186,000 after buying an additional 80,324 shares during the period. Geode Capital Management LLC raised its holdings in shares of NeuroPace by 8.7% in the 3rd quarter. Geode Capital Management LLC now owns 317,192 shares of the company’s stock valued at $2,211,000 after buying an additional 25,330 shares during the period. State Street Corp raised its holdings in shares of NeuroPace by 9.1% in the 3rd quarter. State Street Corp now owns 155,490 shares of the company’s stock valued at $1,084,000 after buying an additional 12,912 shares during the period. Finally, Acadian Asset Management LLC increased its holdings in NeuroPace by 46.0% during the 2nd quarter. Acadian Asset Management LLC now owns 68,918 shares of the company’s stock worth $520,000 after purchasing an additional 21,703 shares during the period. Hedge funds and other institutional investors own 78.83% of the company’s stock.

NeuroPace Stock Performance

NASDAQ NPCE opened at $11.97 on Tuesday. The stock’s fifty day moving average is $10.82 and its two-hundred day moving average is $8.40. The firm has a market capitalization of $357.28 million, a P/E ratio of -11.97 and a beta of 2.02. The company has a debt-to-equity ratio of 6.03, a quick ratio of 4.77 and a current ratio of 5.59. NeuroPace has a fifty-two week low of $5.45 and a fifty-two week high of $18.15.

NeuroPace (NASDAQ:NPCE) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.07. The company had revenue of $21.06 million for the quarter, compared to analyst estimates of $19.33 million. NeuroPace had a negative return on equity of 205.41% and a negative net margin of 36.74%. During the same quarter in the previous year, the company posted ($0.28) earnings per share. On average, research analysts anticipate that NeuroPace will post -1 earnings per share for the current year.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.